Vincerx Pharma soars on QumulusAI merger deal
Shares of drug developer Vincerx Pharma VINC.O rise as much as 47% to $1.22
VINC is planning to merge with QumulusAI, a private company that provides high-performance computing infrastructure for AI, the companies say
The planned merger would make QumulusAI a publicly traded company; QumulusAI shareholders would own about 95% of the combined company, while VINC shareholders would own the rest
Proposed deal values QumulusAI at around $285 million and Vincerx at around $15 million
Following close of deal, QumulusAI would have a say on the combined company's management team and board of directors
Stock fell 77.7% in 2024
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







